Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

Overview

cited authors

Godwin, John E.; Mattar, Bassam; Maris, Michael; Bachier, Carlos; Stevens, Don; Hoda, Daanish; Varela, Juan C.; Cherry, Mohamad; Fanning, Suzanne; Essell, James; Yimer, Habte; Courtright, Jay; Sharman, Jeff P.; Espinola, Ricardo; Mailley, Connor; Avilion, Ariel; Ogasawara, Ken; Ou, San-San; Shaughnessy, Paul

Publication Date

November 23, 2021

webpage

Web of Science

published in

BLOOD Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.